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Abstract
Background: Atrial fibrillation (AF) is the most common cardiac complication of hyperthy-
roidism. The influence of the time of cardioversion on hyperthyroidism-induced AF remains
unclear. The aim of this study was to compare short-term outcomes of early electrical
cardioversion for AF in hyperthyroid and euthyroid patients.
Methods and Results: Sixty-seven subjects with persistent AF (duration, 10 days–12 months)
were divided into two groups according to thyroid function: Euthyroid (Group 1, n = 36,
female/male: 23/13, mean age: 61.77 ± 10.45 years) and hyperthyroid (Group 2, n = 31,
female/male: 10/21, mean age: 65.43 ± 6.40 years). Two patients were excluded for unsuc-
cessful cardioversion (one in each group). In Group 2, 19 patients had clinical and 11 had
subclinical hyperthyroidism. Following transthoracic and transesophageal echocardiography,
cardioversion was performed until the highest energy was reached (270 J) or until sinus
rhythm was achieved. AF recurrence was detected in 13 of 35 patients (37.1%) in Group 1 and
in 11 of 30 patients (36.9%) in Group 2 (p = 0.96) at one month. Recurrence rate was higher
in the clinical hyperthyroid patients than in the subclinical hyperthyroid patients (52.6% vs
9.1%, p = 0.021), but neither the clinical nor the subclinical hyperthyroid subgroups were signifi-
cantly different from Group 1 in terms of recurrence rate (p = 0.27 and p = 0.13, respectively).
Conclusions: Electrical cardioversion should be performed for patients with persistent AF
and hyperthyroidism as soon as possible. (Cardiol J 2012; 19, 1: 53–60)
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Introduction
Atrial fibrillation (AF) is the most common car-
diac complication of hyperthyroidism [1, 2]. The
prevalence of AF is 10% to 15% in hyperthyroid
patients without heart disease, compared to 4% in
the general population [3–5]. Prevalence increases
to 25–40% for hyperthyroid patients aged over
60 years [5]. Besides clinical hyperthyroidism, sub-
clinical hyperthyroidism is associated with a 3–5-
-fold increased risk of AF [5–8].
Atrial fibrillation in hyperthyroidism is associa-
ted with significant mortality and morbidity due to
the high incidence of thromboembolic events and
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heart failure, especially in the elderly [3, 4, 9, 10].
The risk of arterial embolism in particular is high-
er during active thyrotoxicosis than on reversion
to sinus rhythm (SR), and on euthyroid state [9]. It
was recently shown that patients with hyperthyroi-
dism-induced AF have a significantly greater risk of
ischemic stroke (9.4%) than hyperthyroid patients
without AF (0.6%) and AF patients without hyper-
thyroidism (3.1%), particularly within the first
30 days after AF diagnosis [11]. Furthermore, the
risk of thromboembolic events increases with the du-
ration of AF. Therefore, restoring SR as early as pos-
sible is crucial to decrease the risk of fatal complica-
tions in hyperthyroid patients with AF.
The general approach to the treatment of pa-
tients with hyperthyroidism-induced AF is to treat
the hyperthyroidism, which results in conversion
to SR in up to two-thirds of patients [4]. Patients
restore SR within 8–10 weeks after achieving eu-
thyroid state [4, 12], which is a long period consid-
ering the high risk of thromboembolic events. Car-
dioversion is generally suggested for patients re-
maining in AF after achieving euthyroid status [3,
4, 12–14].
The recurrence rate in the medium- (1–2
years) and long-term (over two years) following
cardioversion for hyperthyroidism-induced AF has
been reported to be lower, at around 40–60% [14–
–16], than the more than 80% recurrence rate in
euthyroid patients [16]. Previous studies have re-
ported the short-term (£ one month) recurrence
rate of AF after cardioversion to be 35–60% [17, 18].
But short-term recurrence of AF after cardiover-
sion in hyperthyroid patients has not been studied
so far. If hyperthyroidism-induced AF carries a simi-
lar short-term recurrence rate as AF of non-thyroid
origin after conversion to SR, early electrical car-
dioversion should be considered for hyperthyroid
patients.
In this study, we aimed to determine the short-
-term outcome of early electrical cardioversion for
AF in hyperthyroid patients compared to euthyroid
patients.
Methods
Study design and population
The study was designed as a prospective, con-
trolled study. Sixty-seven subjects who were re-
ferred to the Cardiology Clinic of Bursa Yuksek
Ihtisas Education and Research Hospital between
January 2006 and August 2007 for persistent AF
lasting longer than seven days were included in the
study. The exclusion criteria were: New York Heart
Association (NYHA) class III–IV congestive heart
failure [19], significant native or prosthetic valvu-
lar disease, previous valve surgery, previous elec-
trical or medical cardioversion for AF, significant
left ventricular dysfunction, severe left atrial en-
largement (> 5 cm) and left atrial thrombus in
transesophageal echocardiography (TEE), paroxys-
mal AF, sick sinus syndrome, or any contraindica-
tion for anticoagulation. However, during the ini-
tial evaluation period, patients with hyperthyroid-
ism and disorders of thyroid function test which
were related to chronic disease, and patients tak-
ing antithyroid drugs and amiodarone were exclud-
ed. One hundred and thirty three patients had been
assessed for their suitability for the study over the
19 months. Sixty six of the 133 (49.6%) patients
were excluded from the study: 26 because they had
significant valvular heart disease, 22 patients had
NYHA class III–IV congestive heart failure, three
patients had left atrial thrombus, five patients had
previous electrical or medical cardioversion, and ten
patients were taking amiodarone. Fifteen of the 66 pa-
tients (22.7%) had hyperthyroidism and the other
51  (77.3%) had normal thyroid function test. After
excluding these 66, 67 patients (50.4%) were ac-
cepted into the study, and these were divided into
two groups  according to the thyroid function test.
Of the study population of 67, 36 patients with nor-
mal thyroid function test formed Group 1, and the
other 31 patients, with hyperthyroidism, formed
Group 2. Two patients were excluded due to unsuc-
cessful cardioversion (one from each group), mean-
ing that a total of 65 patients (97% of the 67 patients
who were successfully converted; 35 patients in
Group 1 and 30 patients in Group 2) were studied.
Patients gave informed consent prior to any
study-related procedures. The study was approved
by the local ethics committee of Bursa Yuksek Ih-
tisas Education and Research Hospital, and conduct-
ed in accordance with the latest version of the Hel-
sinki Declaration and local regulations.
Study procedures
Initial evaluation of patients included detailed
medical history, physical examination, and thyroid
function tests, which are free triiodothyronine
(T3), free thyroxine (T4), and thyroid stimulating
hormone (TSH, thyrotropin) levels. Patients with
low TSH levels were deemed to have hyperthy-
roidism. These patients formed Group 2 and they
were further divided into clinically evident hyper-
thyroidism (low TSH levels and high free T3 and
T4 levels) or subclinical hyperthyroidism (low
TSH levels and normal free T3 and T4 levels) sub-
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groups (normal range of: TSH levels: 0.34–
–5.60 µIU/mL, free T3 levels: 2.50–4.20 pg/mL, free
T4 levels: 0.58–1.64 pg/dL).
Echocardiographic evaluation
For all patients, transthoracic echocardio-
graphy (TTE) and TEE were performed before car-
dioversion as suggested by the American Society
of Echocardiography. TTE was also performed at
one hour, 24 hours and one month for conventional
echocardiographic measurements after restoring
SR with cardioversion. During echocardiographic
evaluation, 3.5 Mhz probe was used at Vivid 7 Pro
TTE (GE Vingmed, Horten, Norway) and multi-
plane 6 Mhz probe was used at TEE. Left atrium
and left ventricle were measured at parasternal
long-axis view. Left ventricular ejection fraction
was calculated by echocardiography using the mod-
ified Simpson’s method. Left atrial appendage was
clearly viewed with TEE in all patients. The pres-
ence of thrombus or spontaneous echo contrast at
left atrial appendage was evaluated by two-dimen-
sional TEE. For the assessment of contractile func-
tions, pulse wave Doppler was placed in the proxi-
mal one third of the left atrial appendage. In patients
with AF, left atrial appendage filling and emptying
velocities were obtained by the arithmetic mean of
eight consecutive measurements. None of the pa-
tients had any complication during TEE.
Maximum flow rates at aortic, mitral, and tri-
cuspid valves were measured using apical four-
-chamber and five-chamber views in pulsed Doppler
assessment. Atrial function after cardioversion was
evaluated conventionally by calculating the peak
velocity of the early diastolic wave (E) and peak
velocity of the late diastolic wave (A), their ratio
(peak E/A), and the time-velocity integrals of the
peak velocities of the early and late diastolic waves
with pulsed Doppler that was recorded from the
apical four-chamber view, with the sample volume
positioned between the tips of the mitral and tri-
cuspid leaflets in parallel to ventricular inflow.
Cardioversion procedure
Acetylsalicylic acid and intravenous unfractio-
nated heparin (17 U/kg, Nevparin 25,000 IU, MN
Pharmaceuticals, Istanbul, Turkey) were given to
all patients before cardioversion to obtain target
partial thromboplastin time of 1.5–2 times normal.
Patients in Group 1 who did not have intracardiac
thrombus in TTE and TEE evaluation were given
intravenous amiodarone (loading dose, 5 mg/kg;
maintenance dose, 10–15 mg/kg/h for 24 h). Patients
in Group 2 were given beta-blocker as esmolol
infusion (loading dose, 500 mg/kg for 1 min; main-
tenance dose, 0.05 mg/kg/min with 0.05 mg/kg/min
increments every 5 min according to ventricular
rate to reach a maximum dose of 0.2 mg/kg/min)
followed by 50–100 mg oral metoprolol and propy-
lthiouracil (loading dose, 150–300 mg/day for clini-
cal hyperthyroidism or 100 mg/day for subclinical
hyperthyroidism; maintenance dose was deter-
mined according to clinical response). Antiarrhyth-
mic agents and digoxin were stopped before cardio-
version, but antithyroid therapy continued for pa-
tients in Group 2. Sedation was obtained with
intravenous midazolam (following the initial dose
of 3 mg, 1-mg injections until sedation) before car-
dioversion. Transthoracic electrical direct current
(DC) cardioversion was applied to patients under
intensive care unit conditions by giving synchro-
nized biphasic DC with cardioverter-defibrillator
(Cardiolife TEC 5531 Nihon Kohden Corporation,
Japan). The level of energy for cardioversion was
150 J initially, and 200 J and 270 J subsequently.
External biphasic DC shocks were used at the phy-
sician’s discretion until the highest energy was
reached (270 J) or until SR was restored. The car-
dioversion was defined as successful if SR lasted
longer than one minute following cardioversion. Pa-
tients restoring SR had effective anticoagulation (in-
ternational normalized ratio [INR] higher than 2.0)
with warfarin (following the initial dose of 5 mg/day,
dose was adjusted to obtain INR as 2–3) after car-
dioversion for one month. Heart rate and rhythm
were monitored using an electrocardiography
(ECG) monitor and 12-lead ECG.
Amiodarone was continued after discharge
from hospital (orally 200 mg/day for four weeks).
Patients were evaluated at one, two, and four weeks
after discharge by physical examination, ECG,
and INR.
Statistical analysis
SPSS software for Windows (Version 11.5,
2003, SPSS Inc., Chicago, IL, USA) was used for
statistical analysis. Data was presented as mean ±
± standard deviation (SD). Categorical variables
were compared using the Pearson c2 test and Fis-
her’s exact test; continuous variables were com-
pared using Student t test (for normally distributed
data) or Mann-Whitney U test (for other data). The
correlation between the maintenance of SR and oth-
er parameters were evaluated with a Pearson’s cor-
relation analysis. Statistical significance level was
defined as p < 0.05.
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Results
Demographic and clinical findings
There was no difference in the mean age of
patients between Group 1 and Group 2 (61.77 ±
± 10.45 years vs 65.43 ± 6.40 years, respectively,
p = 0.10), but the percentage of men in Group 2
was significantly higher than Group 1 (70% vs
37.1%, p = 0.008; Table 1). Duration of AF was be-
tween ten days and 12 months for both groups
(192.94 ± 146.64 days for Group 1 and 182.16 ±
± 125.84 for Group 2, p = 0.75). Study groups were
comparable in terms of other baseline clinical find-
ings, which were initial heart rate, body surface
area, blood pressure, concomitant chronic diseas-
es, and drugs used (Table 1).
According to laboratory evaluation of thyroid
function, mean TSH level was 2.46 ± 1.42 and
0.028 ± 0.024 (p < 0.001), free T3 level was 2.57 ±
± 0.56 and 6.22 ± 5.29 (p = 0.001), and free T4
level was 1.16 ± 0.13 and 2.25 ± 1.18 (p < 0.001)
for euthyroid patients in Group 1 and patients in
Group 2. Clinically evident hypert hyroidism was
determined in 19 patients and subclinical hyperthy-
roidism was determined in 11 patients in Group 2.
Elevated antithyroperoxidase antibody titers and
antithyroglobulin antibody titers were detected in
ten (33%) patients and six (20%) patients, respec-
tively. Graves’s disease was the underlying cause
of hyperthyroidism in two (6.7%) patients, and mul-
tinodular goiter accounted for the remaining 28
(93.3%) patients. At one month clinical follow-up,
we did not see transient ischemic attack, stroke, or
death in either group.
Echocardiographic findings
Left ventricular ejection fraction was 63.34 ±
± 5.81% for Group 1 and 60.66 ± 5.88% for Group 2
(p = 0.41). Left atrium diameter was 4.38 ± 0.32 cm
and 4.41 ± 0.37 cm for Group 1 and Group 2, re-
spectively (p = 0.75). Other echocardiographic
parameters before cardioversion were also similar
in Group 1 and Group 2 (Table 2).
There was no significant difference between
Group 1 and Group 2 in terms of left atrial append-
age outflow or inflow velocities (Table 2). Mitral E
velocity (0.79 ± 0.16 ms for Group 1 and 0.79 ±
0.14 ms for Group 2, p = 0.99) and tricuspid E
velocity (0.48 ± 0.28 ms for Group 1 and 0.50 ±
± 0.12 ms for Group 2, p = 0.36) in pulsed Dop-
Table 1. Basic demographic and clinical characteristics of patients in Group 1 and Group 2.
Group 1 Group 2 P
(control, n = 35)  (hyperthyroidism, n = 30)
Age [years] 61.77 ± 10.45 65.43 ± 6.40 0.10
Gender (men/women) 13 (37.1%)/22 (62.9%) 21 (70%)/9 (30%) 0.008
Duration of atrial fibrillation [days] 192.94 ± 146.64 182.16 ± 125.84 0.75
Initial heart rate [bpm] 109.02 ± 20.54 112.13 ± 18.43 0.52
Body surface area [m²] 1.79 ± 0.19 1.73 ± 0.16 0.17
Systolic blood pressure [mm Hg] 138.14 ± 17.66 140.63 ± 17.13 0.56
Diastolic blood pressure [mm Hg] 85.14 ± 10.60 86.83 ± 9.51 0.50
Chronic diseases:
Diabetes mellitus 3 (8.6%) 0 (0%) 0.10
Hypertension 28 (80%) 23 (76.7%) 0.74
Dislipidemia 3 (8.6%) 2 (6.7%) 0.77
Coronary artery disease 1 (2.9%) 0 (0%) 0.35
Smoking 3 (8.6%) 5 (16.7%) 0.32
Drugs:
Acetylsalicylic acid 32 (91.4%) 28 (93.3%) 0.77
Beta-blocker 23 (65.7%) 26 (86.7%) 0.051
Calcium channel blocker 1 (2.9%) 1 (3.3%) 0.91
ACE inhibitor 27 (77.1%) 23 (76.7%) 0.96
Angiotensin receptor blocker 3 (8.6%) 1 (3.3%) 0.38
Antilipidemic 1 (2.9%) 0 (0%) 0.35
Diuretic 1 (2.9%) 0 (0%) 0.35
Data is given as mean ± standard deviation or n (%)
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pler were comparable between the study groups.
Atrial function parameters at one hour (mitral A
velocity, tricuspid A velocity, mitral E/A ratio,
tricuspid E/A ratio, and mitral A time-velocity in-
tegral), at 24 h (mitral A velocity), and at one
month (left atrium diameter) after cardioversion
were also similar between Group 1 and Group 2
(Table 2).
Cardioversion and recurrence
of atrial fibrillation
For all patients, SR was restored immediately
after cardioversion and was maintained for 30 min.
The mean total energy of cardioversion was
221.42 ± 46.15 J in Group 1 and 215.66 ± 46.06 J in
Group 2 (p = 0.61). Patients were followed up to
one month. Atrial fibrillation recurrence rate was
similar in Group 1 and Group 2 at the end of the
first month; recurrence was detected in 13 of 35 pa-
tients (37.1%) in Group 1 and in 11 of 30 patients
(36.9%) in Group 2 (p = 0.96) at the end of the first
month (Fig. 1). No complication was recorded in
patients who received anticoagulant treatment for
one month following cardioversion.
The AF recurrence rate at the end of the first
month was significantly higher among patients with
clinically evident hyperthyroidism than patients
with subclinical hyperthyroidism in Group 2 (52.6%
and 9.1%, respectively, p = 0.023). However, there
was no statistically significant difference in AF re-
currence rates between patients with clinically evi-
dent hyperthyroidism and Group 1 (52.6% and
37.1%, respectively, p = 0.27) and patients with
subclinical hyperthyroidism and Group 1 (9.1% and
37.1%, respectively, p = 0.13; Fig. 1).
According to correlation analysis, we found a si-
gnificant negative correlation between SR mainte-
nance and duration of AF (r = –0.48, p < 0.001) and
corrected left atrial diameter according to body sur-
face area (r = –0.27, p = 0.02) but we did not show
a significant correlation between SR maintenance
and age (r = –0.10, p = 0.42), TSH (r = –0.10,
p = 0.41), free T3 (r = –0.07, p = 0.56), or free T4
(r = –0.16, p = 0.18) levels.
Table 2. Echocardiographic findings in Group 1 and Group 2.
Group 1 Group 2 P
(control, n = 35) (hyperthyroidism, n = 30)
Left atrium diameter [cm] 4.38 ± 0.32 4.41 ± 0.37 0.75
Left ventricular end-systolic diameter [cm] 3.19 ± 0.12 3.28 ± 0.16 0.37
Left ventricular end-diastolic diameter [cm] 4.80 ± 0.65 4.72 ± 0.11 0.54
Septal wall thickness [cm] 1.13 ± 0.14 1.18 ± 0.17 0.24
Posterior wall thickness [cm] 1.11 ± 0.12 1.13 ± 0.12 0.48
Left ventricular ejection fraction [%] 63.34 ± 5.81 60.66 ± 5.88 0.41
Fractional shortening [%] 33.65 ± 4.77 32.03 ± 5.50 0.20
End-systolic volume [mL] 32.71 ± 10.16 37.26 ± 13.90 0.13
End-diastolic volume [mL] 93.97 ± 20.78 99.03 ± 24.72 0.37
Pulmonary artery pressure [mm Hg] 40.62 ± 8.23 43.36 ± 10.42 0.26
LA appendage peak outflow velocity [cm/s] 0.48 ± 0.12 0.49 ± 0.07 0.73
LA appendage mean outflow velocity [cm/s] 0.38 ± 0.10 0.38 ± 0.06 0.97
LA appendage peak inflow velocity [cm/s] 0.50 ± 0.13 0.51 ± 0.08 0.82
LA appendage mean inflow velocity [cm/s] 0.40 ± 0.09 0.41 ± 0.07 0.90
Mitral E velocity [m/s] 0.79 ± 0.16 0.79 ± 0.14 0.99
Tricuspid E velocity [m/s] 0.48 ± 0.28 0.50 ± 0.12 0.36
Mitral A velocity at one hour [m/s] 0.43 ± 0.16 0.47 ± 0.16 0.42
Tricuspid A velocity at one hour [m/s] 0.35 ± 0.18 0.34 ± 0.17 0.86
Mitral E/A ratio at one hour 2.02 ± 0.79 1.83 ± 0.63 0.31
Tricuspid E/A ratio at one hour 1.44 ± 0.44 1.49 ± 0.40 0.63
Mitral A time-velocity integral at one hour [cm] 4.65 ± 2.00 4.79 ± 1.73 0.77
Mitral A velocity at 24 hours [m/s] 0.50 ± 0.17 0.67 ± 0.26 0.24
Left atrium diameter at one month [cm] 4.21 ± 0.30 4.29 ± 0.32 0.45
Data is given as mean ± standard deviation; LA — left atrial; E — early diastolic wave; A — late diastolic wave
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Discussion
In this prospective, randomized, parallel group,
and controlled study, we evaluated the short-term
(one month) outcome of early electrical cardiover-
sion in hyperthyroidism-induced AF compared to
euthyroid AF. We found that the short-term out-
come of early electrical cardioversion is similar in
hyperthyroid and euthyroid patients, suggesting
that early electrical cardioversion may be applied
for hyperthyroidism-induced AF even before euthy-
roid status is achieved.
Cardiac events associated with hyperthyroidism,
the most common of which is AF, are the most fre-
quent and most serious complications of the dise-
ase. In a population-based study on 40,628 patients
with hyperthyroidism, 8.3% had AF or flutter with-
in 30 days of the diagnosis of hyperthyroidism [20].
Hyperthyroid patients with male sex, increasing
age, ischemic heart disease, congestive heart fail-
ure, and heart valve disease have a particularly in-
creased risk of AF [20]. In another large study in-
cluding more than 23,000 subjects, AF was detect-
ed in 2.3% of euthyroid subjects, and in 12.7% and
13.8% of the subjects with subclinical and overt
hyperthyroidism, respectively [6].
Patients with hyperthyroidism and without
heart disease have an increased incidence of abnor-
mal supraventricular premature depolarizations and
nonsustained tachycardias [21]. The main mecha-
nisms for the increased risk of AF in hyperthyroi-
dism are alterations in cellular membrane function
causing shortening of the atrial refractory period,
triggered activity in the pulmonary vein cardiomyo-
cytes, increased supraventricular ectopic activity,
and activation of these arrhythmogenic foci by ele-
vated thyroid hormones [4, 5, 21]. Thyroid hor-
mones act directly through nuclear thyroid recep-
tors causing increased gene transcription of cardiac
myocyte proteins [4]. Thyroid hormones increase
heart rate, ventricular contractility and cardiac hy-
pertrophy by upregulating sarcoplasmic calcium
ATPase which plays a central role in myocardial
contractility [22], myosin heavy chain alpha, volt-
age gated K+ channels, Na+ channels and beta1
adrenergic receptors [4]. However, as we have pre-
viously reported [23], left atrial appendage functions
evaluated by TEE are not altered in patients with
hyperthyroidism.
Atrial fibrillation is an independent risk factor
for cardiovascular thromboembolic events [9]. It
carries a 3–6% risk of thromboembolic complica-
tions, which is 5–7 times greater than that of sub-
jects with SR [24]. Atrial fibrillation increases the
risk of blood clot formation inside the heart due to
rapid and irregular heartbeat causing embolism,
stroke, silent cerebral infarction and other disorders
[9]. Siu et al. [11] recently showed that there was
an increased risk of ischemic stroke for hyperthy-
roid patients with new-onset AF during the early
phase following diagnosis. Therefore, hyperthyroi-
dism-induced AF should be treated promptly. The
general treatment approach is antithyroid therapy
and elective cardioversion for patients who main-
tain a euthyroid state but are still in AF [3, 12].
Atrial fibrillation usually disappears upon norma-
lization of T4 and T3 hormone levels with antithy-
roid treatment [12]. Systemic anticoagulation is also
indicated in the presence of AF to prevent fatal com-
plications, and should be continued until SR has
been present for at least three months [2, 25]. Al-
though most patients respond to this treatment
approach, patients are at high risk of thromboem-
bolic complications and may need to be treated with
anticoagulants for long periods until SR is restored.
Therefore, many authors have suggested early car-
dioversion in the treatment of hyperthyroidism-
-induced AF, taking into account the medium- and
long-term outcomes of patients [16].
Since duration of AF is the main determinant
of duration and severity of atrial stunning [26], re-
storing SR as early as possible reverses atrial stun-
ning and thus decreases the risk of thromboembo-
lic complications. Therefore, early electrical car-
dioversion before antithyroid therapy should be
Figure 1. Atrial fibrillation recurrence rate at the end
of the first month among patients in Group 1 (control,
n = 35), Group 2 (hyperthyroidism, n = 30), and sub-
groups of Group 2, which were clinically evident hyper-
thyroidism (n = 19) and subclinical hyperthyroidism
(n = 11); HT — hyperthyroidism.
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considered for hyperthyroidism-induced AF to mini-
mize the risk of thromboembolic complications.
Nakazawa et al. [15] evaluated the outcome of
cardioversion in patients with thyrotoxicosis-indu-
ced AF for a median duration of 28.5 months. They
reported that 98 out of 106 patients were success-
fully cardioverted and at late follow-up (mean
80.6 months), 67% were in SR [15]. In a recent
study by Siu et al. [16], the AF recurrence rate dur-
ing a 24 month follow-up period after successful
electrical cardioversion was 59% for patients with
hyperthyroidism-induced AF, vs 83% in AF of non-
-thyroid origins (p = 0.04).
Thus, hyperthyroidism-induced AF carries
a lower recurrence rate after conversion to SR than
non-hyperthyroidism-induced AF, and early electri-
cal cardioversion should be considered. But the out-
come of early electrical cardioversion performed with-
out waiting for a euthyroid state has not been report-
ed in the literature. In the present study, we aimed to
determine the short-term outcome of early electrical
cardioversion in hyperthyroidism-induced AF.
We found that AF recurrence rate was similar
in euthyroid and hyperthyroid groups at the end of
the first month (37.1% vs 36.9%, respectively, p =
= 0.96). In other words, 62.9% of euthyroid patients
and 63.3% of hyperthyroid patients were at SR at
one month following cardioversion. The short-term
(£ one month) recurrence rate of AF after cardio-
version in our study was similar to the rates report-
ed in the literature. Ari et al. [27] showed that 20 of
58 patients (34.5%) with persistent AF reverted to
AF during the six months following successful elec-
trical cardioversion. Vikman et al. [17] reported a one
month recurrence rate of 35% among 78 patients
with persistent AF after restoration of SR with elec-
trical cardioversion. Tieleman et al. [18] reported
a higher recurrence rate during one month of follow-
up: 35 out of 61 patients (57%) had a relapse of AF
in their study. The variability in the short-term re-
currence rate following cardioversion in these stud-
ies may be explained with differing baseline patient
characteristics such as advanced age [28] and dura-
tion of AF study populations [17, 18].
It should also be noted that Group 1 was treat-
ed with amiodarone, while Group 2 was given beta-
-blocker due to the negative effects of amiodarone
on thyroid functions. It is remarkable that although
amiodarone is effective [29], and superior to beta-
-blockers in preventing AF recurrence [30], euthy-
roid and hyperthyroid groups showed similar recur-
rence rates in our study.
Another important finding of our study is that
the AF recurrence rate at one month was signifi-
cantly higher in clinically evident hyperthyroidism
than subclinical hyperthyroidism (52.6% and 9.1%,
respectively, p = 0.023). However, neither the clini-
cally evident hyperthyroidism group nor the sub-
clinical hyperthyroidism group was not shown statis-
tically significant difference from the euthyroid con-
trol group in terms of AF recurrence rate (p = 0.27
and p = 0.13, respectively). This shows that early
electrical cardioversion may be applied in patients
with both clinical and subclinical hyperthyroidism,
but it may be more effective in patients with subcli-
nical hyperthyrodism for prevention of AF recurrence.
As shown in previous studies [17, 18], we found
a significant correlation between SR maintenance
and duration of AF and left atrial diameter. But we
did not find a correlation between SR maintenance
and thyroid function test. These results support the
opinion that cardioversion should be performed in
patients with persistent AF and hyperthyroidism as
soon as possible.
The major limitations of this study were the small
sample size and short follow-up duration. In spite of
the limited number of patients, our study presents
a treatment alternative for hyperthyroid patients with
AF to prevent fatal complications. The preliminary
findings of the present study should be confirmed by
further controlled clinical studies with a larger sam-
ple size and longer follow-up duration to evaluate the
medium- and long-term outcomes of early cardiover-
sion in AF induced by hyperthyroidism.
Conclusions
The short-term (one month) recurrence rates
following early electrical cardioversion for AF are
similar for hyperthyroid and euthyroid patients.
Thus, early electrical cardioversion should be con-
sidered for hyperthyroidism-induced AF, particu-
larly for subclinical hyperthyroid patients, without
waiting for a euthyroid state. This would decrease
the risk of thromboembolic complications by restor-
ing SR promptly. Further prospective studies with
a large sample size are needed to confirm the advan-
tages of early electrical cardioversion during treat-
ment algorithm of hyperthyroidism-induced AF.
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